Introduction: Whether the weight-loss plateau and its values differ in obesity with or without metabolic dysfunction-associated steatotic liver disease (MASLD) undergoing continuous lifestyle intervention remains unknown. We aimed to investigate this problem.
Methods: This prospective observational cohort study included 305 patients with obesity and MASLD and 103 matched individuals with non-MASLD from January 2015 to April 2023, with a 12-month follow-up to monitor weight changes. Liver biochemistry, liver fat content with MRI-PDFF, and liver stiffness measurement via 2D-SWE were assessed at baseline and after 12 months. A validated weight trajectory regression model was applied to estimate the weight loss plateau.
Results: Individuals with MASLD and non-MASLD presented a similar timing of the weight plateau at 6 months, but patients with MASLD experienced less weight loss and maintained their weight plateaus longer compared to those with non-MASLD. Among patients with MASLD, a greater total weight loss (TWL) at 6 months was associated with better treatment response in hepatic steatosis and injury (all P<0.001). Further multivariate logistic analysis showed that the 6-month TWL was an independent predictor of subsequent improvements in hepatic steatosis (OR: 0.78, 95%CI: 0.72-0.84) and alanine aminotransferase levels (OR: 0.82, 95%CI: 0.76-0.90) at 12 months.
Conclusion: Patients with MASLD experienced gradual weight loss followed by a prolonged plateau, with the maximum reduction observed at 6 months. The degree of 6-month weight loss was a valuable prognostic factor for the 12-month hepatic treatment outcomes. Strategies to overcome this plateau are essential for improving long-term treatment efficacy in MASLD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000543818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Serious Bacterial and Non-Bacterial Infections in People With MASLD.
Liver Int
April 2025
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. MASLD is a multisystem disease where metabolic dysfunction plays a key role in the development of MASLD and its most relevant liver-related morbidities and extrahepatic complications, such as cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers. Among the least examined MASLD-related extrahepatic complications, an ever-increasing number of observational studies have reported a positive association between MASLD and the risk of serious bacterial infections (SBI) requiring hospital admission.
View Article and Find Full Text PDFTherapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.
Ann Pharmacother
March 2025
Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD).
Data Sources: A literature review was conducted using the search terms , , , , , and on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data.
Study Selection And Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion.
Using non-invasive indicators to screen the PCOS population for liver disease - a single-centre study.
Endokrynol Pol
March 2025
Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Introduction: Studies show an association between polycystic ovary syndrome (PCOS) and an increased incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) in this patient group. Diagnostic tools that can screen relevant groups of PCOS' patients for liver disease are still being sought.
Material And Methods: Our study included 242 patients with PCOS diagnosed on the basis of the Rotterdam criteria, which we divided according to phenotypes.
Hormone correction of dysfunctional metabolic gene expression in stem cell-derived liver tissue.
Stem Cell Res Ther
March 2025
Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh BioQuarter, Edinburgh, EH16 4UU, UK.
The increase in metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression to metabolic dysfunction-associated steatohepatitis (MASH) is a worldwide healthcare challenge. Heterogeneity between men and women in the prevalence and mechanisms of MASLD and MASH is related to differential sex hormone signalling within the liver, and declining hormone levels during aging. In this study we used biochemically characterised pluripotent stem cell derived 3D liver spheres to model the protective effects of testosterone and estrogen signalling on metabolic liver disease 'in the dish'.
View Article and Find Full Text PDFImpact of blood lead and manganese levels on metabolic dysfunction-associated steatotic liver disease prevalence: insights from NHANES (2017-2020).
BMC Gastroenterol
March 2025
Ningbo medical center Lihuili Hospital of Ningbo University, Ningbo, 315040, Zhejiang, People's Republic of China.
Background: The metabolic dysfunction-associated steatotic liver disease (MASLD) paradigm represents a significant departure from the previous nonalcoholic fatty liver disease (NAFLD) framework, offering a non-stigmatizing approach that enhances awareness and accelerates patient understanding. Our primary aim was to investigate the potential relationship between blood lead and manganese exposure and the onset of MASLD.
Methods: Using data from the National Health and Nutrition Examination Survey (NHANES) database spanning from 2017 to 2020, a cross-sectional study included 4,475 participants was performed to assess the relationship.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!